MCID: INT143
MIFTS: 63

Interstitial Cystitis

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Interstitial Cystitis

MalaCards integrated aliases for Interstitial Cystitis:

Name: Interstitial Cystitis 12 72 49 55 36 40 3 14 69
Painful Bladder Syndrome 49 55 69
Bladder Pain Syndrome 49 55 69
Interstitial Cystitis/painful Bladder Syndrome 49 55
Interstitial Cystitis/bladder Pain Syndrome 49 55
Trigonitis 49 69
Ic/bps 49 55
Ic/pbs 49 55
Ic 49 3
Chronic Interstitial Cystitis 69
Pelvic Congestion Syndrome 69
Cystitis, Interstitial 41
Pelvic Pain Syndrome 49
Ulcerative Cystitis 12
Pelvic Pain 40
Pbs 49

Characteristics:

Orphanet epidemiological data:

55
interstitial cystitis
Prevalence: 1-5/10000 (Finland),1-5/10000 (United States),1-9/1000000 (Finland); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:13949
MeSH 41 D018856
NCIt 46 C27189
SNOMED-CT 64 111409009 197834003
Orphanet 55 ORPHA37202
MESH via Orphanet 42 D018856
UMLS via Orphanet 70 C0282488 C0600040 C3160917 more
ICD10 via Orphanet 33 N30.1
KEGG 36 H01551
ICD10 32 N30.1

Summaries for Interstitial Cystitis

NIH Rare Diseases : 49 Interstitial cystitis (IC) is a chronic condition that causes painful urinary symptoms. Symptoms and severity can vary. Some people may have only mild discomfort, or feel tenderness or pressure in the bladder or pelvis. Others may experience intense bladder pain, urgent or frequent needs to urinate, or pain during sexual intercourse. Symptoms may be constant, or they may come and go. Some people with IC have Hunner's ulcers (areas of inflammation on the bladder wall, identified by cytoscopy). The exact cause of IC is not known. While the symptoms are similar to those of a bladder infection, IC is not an infection. It occurs more commonly in women, and in people with other chronic pain disorders such as irritable bowel syndrome or fibromyalgia. There is no cure for IC, but there are treatment options to help relieve the symptoms. No single treatment works for all people with IC. Often, people try different treatments or combinations of treatments before finding something that works. Treatment options may include lifestyle changes, oral or topical medications, bladder instillations, neuromodulation therapy, Botox injections in the bladder muscles, and surgery (in rare cases). Without treatment, IC can affect a person's sleep, daily activities, and social life. Last updated: 10/4/2017

MalaCards based summary : Interstitial Cystitis, also known as painful bladder syndrome, is related to bladder disease and pulmonary disease, chronic obstructive, and has symptoms including pollakisuria, urinary bladder inflammation and abnormality of the vagina. An important gene associated with Interstitial Cystitis is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Acetylcholine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and prostate, and related phenotypes are behavior/neurological and growth/size/body region

MedlinePlus : 40 Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better. They include Distending, or inflating, the bladder Bathing the inside of the bladder with a drug solution Oral medicines Electrical nerve stimulation Physical therapy Lifestyle changes Bladder training In rare cases, surgery NIH: National Institute of Diabetes and Digestive and Kidney Diseases

CDC : 3 Interstitial Cystitis (IC) is a chronic bladder condition resulting in recurring discomfort or pain in the bladder or surrounding pelvic region. People with IC usually have inflamed or irritated bladder walls which can cause scarring and stiffening of the bladder. 

Wikipedia : 72 Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that... more...

Related Diseases for Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Related Disease Score Top Affiliating Genes
1 bladder disease 30.5 HBEGF IL6 NGF P2RX3 TAC1 TRPV1
2 pulmonary disease, chronic obstructive 29.8 ADRB2 CXCL8 IL6
3 chronic cystitis 29.8 NGF UPK3A
4 esophagitis 29.7 CXCL8 IL6 TRPV1
5 paine syndrome 29.7 BDNF NGF TAC1 TRPV1 UPK3A
6 cystitis 29.6 CXCL8 EGF HBEGF IL6 KNG1 NGF
7 bladder cancer 29.3 CDH1 CXCL8 EGF HBEGF UPK3A
8 somatoform disorder 29.0 IL4 NGF TAC1 TRPV1
9 asthma 26.6 ADRB2 BDNF CXCL8 IL4 IL6 KNG1
10 chronic interstitial cystitis 12.4
11 congenital disorder of glycosylation, type ic 12.3
12 pseudohypoparathyroidism, type ic 12.3
13 cutis laxa, autosomal recessive, type ic 12.1
14 usher syndrome, type ic 12.1
15 neuropathy, hereditary sensory and autonomic, type ic 12.0
16 amelogenesis imperfecta, type ic 12.0
17 glycogen storage disease ic 12.0
18 lymphedema, hereditary, ic 12.0
19 prune belly syndrome 11.9
20 isolated focal cortical dysplasia type ic 11.9
21 iridocorneal endothelial syndrome 11.8
22 alg6-congenital disorder of glycosylation 11.7
23 urethral syndrome 11.4
24 chronic pain 11.4
25 plastic bronchitis 11.2
26 myasthenic syndrome, congenital, 5 11.2
27 charcot-marie-tooth disease, demyelinating, type 1c 11.2
28 ichthyosis--cheek--eyebrow syndrome 11.1
29 corneal endothelial dystrophy 11.1
30 cogan-reese syndrome 11.1
31 convulsions, familial infantile, with paroxysmal choreoathetosis 11.0
32 ciliary dyskinesia, primary, 1 11.0
33 muscular dystrophy, limb-girdle, type 1c 11.0
34 autosomal dominant limb-girdle muscular dystrophy type 1c 11.0
35 episodic pain syndrome, familial, 1 10.9
36 navicular bone, accessory 10.8
37 congenital disorder of glycosylation, type ib 10.8
38 tendinitis 10.8
39 joint disorders 10.8
40 pica disease 10.8
41 diarrhea 10.8
42 cholera 10.8
43 bursitis 10.8
44 persistent genital arousal disorder 10.8
45 piriformis syndrome 10.8
46 chylomicronemia, familial, due to circulating inhibitor of lipoprotein lipase 10.8
47 primary ciliary dyskinesia 10.8
48 recurrent corneal erosion 10.4 CXCL8 IL6
49 bagassosis 10.4 CXCL8 IL6
50 acute transverse myelitis 10.4 CXCL8 IL6

Comorbidity relations with Interstitial Cystitis via Phenotypic Disease Network (PDN):


Acute Cystitis Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Interstitial Cystitis:



Diseases related to Interstitial Cystitis

Symptoms & Phenotypes for Interstitial Cystitis

Human phenotypes related to Interstitial Cystitis:

55 31 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pollakisuria 55 31 hallmark (90%) Very frequent (99-80%) HP:0100515
2 urinary bladder inflammation 55 31 hallmark (90%) Very frequent (99-80%) HP:0100577
3 abnormality of the vagina 55 31 occasional (7.5%) Occasional (29-5%) HP:0000142
4 urinary urgency 55 31 hallmark (90%) Very frequent (99-80%) HP:0000012
5 nocturia 55 31 hallmark (90%) Very frequent (99-80%) HP:0000017
6 abnormality of the labia 55 31 hallmark (90%) Very frequent (99-80%) HP:0000058
7 abnormality of the menstrual cycle 55 31 hallmark (90%) Very frequent (99-80%) HP:0000140
8 abnormality of the urethra 55 31 hallmark (90%) Very frequent (99-80%) HP:0000795
9 pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0012531
10 dyspareunia 55 31 hallmark (90%) Very frequent (99-80%) HP:0030016
11 functional abnormality of the bladder 55 Very frequent (99-80%)
12 abnormality of the bladder 55 Very frequent (99-80%)
13 abnormality of the genital system 55 Very frequent (99-80%)

UMLS symptoms related to Interstitial Cystitis:


female genital pain and other symptoms, other specified symptoms associated with female genital organs, pain and other symptoms associated with female genital organs, mittelschmerz, unspecified symptom associated with female genital organs

MGI Mouse Phenotypes related to Interstitial Cystitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 ADRB2 NGF BDNF P2RX3 TAC1 HBEGF
2 growth/size/body region MP:0005378 10 ADRB2 KNG1 NGF BDNF CDH1 EGF
3 cardiovascular system MP:0005385 9.92 ADRB2 NGF P2RX3 CDH1 TAC1 HBEGF
4 homeostasis/metabolism MP:0005376 9.9 ADRB2 NGF BDNF P2RX3 CDH1 HBEGF
5 integument MP:0010771 9.65 NGF BDNF P2RX3 CDH1 TAC1 EGF
6 renal/urinary system MP:0005367 9.1 TAC1 TRPV1 IL4 UMOD UPK3A IL6

Drugs & Therapeutics for Interstitial Cystitis

Drugs for Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
2
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
3
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
4
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Cycloserine Approved Phase 4 68-41-7 6234 401
8
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 abobotulinumtoxinA Phase 4,Phase 2,Phase 1
13 Botulinum Toxins Phase 4,Phase 2,Phase 1
14 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 1
15 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Neuromuscular Agents Phase 4,Phase 2,Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
18 onabotulinumtoxinA Phase 4,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
21 Anti-Arrhythmia Agents Phase 4,Phase 2
22 Adrenergic Agents Phase 4,Phase 3
23 Adrenergic Agonists Phase 4,Phase 3
24 Adrenergic alpha-2 Receptor Agonists Phase 4
25 Adrenergic alpha-Agonists Phase 4
26 Analgesics Phase 4,Phase 3,Phase 2
27 Analgesics, Non-Narcotic Phase 4,Phase 3
28 Anti-Anxiety Agents Phase 4
29 Hypnotics and Sedatives Phase 4
30 Oxytocics Phase 4
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4
33 Antirheumatic Agents Phase 4,Phase 3,Phase 2
34 Cyclooxygenase Inhibitors Phase 4
35 Ketorolac Tromethamine Phase 4
36 Analgesics, Opioid Phase 4,Phase 2
37 Narcotics Phase 4,Phase 2
38 Opiate Alkaloids Phase 4
39 Anti-Bacterial Agents Phase 4,Phase 3
40 Antibiotics, Antitubercular Phase 4,Phase 3
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2
42 Antimetabolites Phase 4
43 Antitubercular Agents Phase 4,Phase 3
44 Renal Agents Phase 4
45 Autonomic Agents Phase 4,Phase 3
46 Anticoagulants Phase 4,Phase 2
47 Antiparkinson Agents Phase 4,Phase 3
48 Calcium, Dietary Phase 4,Phase 2
49 Psychotropic Drugs Phase 4,Phase 3
50 Tranquilizing Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 142)

# Name Status NCT ID Phase Drugs
1 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
2 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
3 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
4 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
5 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
6 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
7 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
8 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
9 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
10 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Recruiting NCT01312259 Phase 4
11 Chronic Pain Risk Associated With Menstrual Period Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
12 Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Terminated NCT00086684 Phase 4 Pentosan polysulfate sodium 100 mg;Placebo;Pentosan polysulfate sodium 100 mg
13 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
14 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
15 Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms Unknown status NCT00094874 Phase 3
16 Efficacy Study of Adalimumab to Treat Interstitial Cystitis Completed NCT01295814 Phase 3 Adalimumab
17 Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome Completed NCT01294878 Phase 3 omalizumab
18 URACYST® For the Treatment of GAG Deficient Interstitial Cystitis Completed NCT00150488 Phase 2, Phase 3
19 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) Completed NCT00124306 Phase 3 Amitriptyline
20 A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Completed NCT02497287 Phase 3 Esketamine (Intranasal Spray);Duloxetine (Oral Antidepressant);Escitalopram (Oral Antidepressant);Sertraline (Oral Antidepressant);Venlafaxine Extended Release (XR) (Oral Antidepressant)
21 A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis Recruiting NCT02787083 Phase 3 Mirabegron;Placebo
22 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
23 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Active, not recruiting NCT02497976 Phase 3 Placebo
24 A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . Terminated NCT00451867 Phase 3 Mycophenolate Mofetil;Mycofenolate Mofetil (MMF);Placebo
25 Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions Unknown status NCT01437579 Phase 2
26 Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action Completed NCT01990898 Phase 2 Cyclosporine
27 Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis Completed NCT01479725 Phase 2
28 Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome Completed NCT00919113 Phase 2 2% sodium chondroitin sulfate;Placebo
29 Interstitial Cystitis Completed NCT00056251 Phase 2
30 An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis Completed NCT00739739 Phase 2 PD 0299685 at 15mg BID;PD 0299685 at 30mg BID;placebo for PD 0299685
31 Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment Completed NCT01969773 Phase 2 Botulinum toxin A;Normal saline instillation
32 Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis Completed NCT00295854 Phase 2 MN-001 BID;MN-001;Placebo
33 A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Completed NCT00527917 Phase 2
34 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Completed NCT02411110 Phase 2
35 Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Completed NCT02247557 Phase 2 Liposome encapsulated BoNT-A;BOTOX 200U in normal saline;Normal saline
36 An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis Completed NCT00601484 Phase 2 PF-04383119;Placebo
37 Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC Completed NCT00420550 Phase 2
38 A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) Completed NCT01613586 Phase 2 ASP3652;Placebo
39 Efficacy and Safety of AQX-1125 in IC/BPS Completed NCT01882543 Phase 2 AQX-1125;Placebo
40 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions Completed NCT02395042 Phase 2 LiRIS®;LiRIS Placebo
41 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
42 Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients Completed NCT01997983 Phase 1, Phase 2
43 The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome Completed NCT01569438 Phase 2 Gefapixant;Sugar Pill
44 Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis Completed NCT00517868 Phase 2 URG101;Placebo
45 OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Completed NCT01197261 Phase 2 Oxycodone naloxone prolonged release tablets;Placebo tablets
46 Study of U101 for Bladder Pain and/or Urgency Completed NCT00256542 Phase 2 Alkalinized Lidocaine-Heparin
47 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression Completed NCT01998958 Phase 2 Esketamine 14 mg;Esketamine 28 mg;Esketamine 56 mg;Esketamine 84 mg;Placebo
48 A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Recruiting NCT03282318 Phase 2 ASP6294;Placebo
49 Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Recruiting NCT02591199 Phase 2 URG101;Placebo;Lidocaine;Heparin
50 Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome Recruiting NCT01393223 Phase 2 LP-08 80mg;Normal Saline Placebo;LP-08 20mg

Search NIH Clinical Center for Interstitial Cystitis

Cochrane evidence based reviews: cystitis, interstitial

Genetic Tests for Interstitial Cystitis

Anatomical Context for Interstitial Cystitis

MalaCards organs/tissues related to Interstitial Cystitis:

38
Testes, Kidney, Prostate, Brain, Skin, Endothelial, Pituitary

Publications for Interstitial Cystitis

Articles related to Interstitial Cystitis:

(show top 50) (show all 439)
# Title Authors Year
1
Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). ( 29341502 )
2018
2
FDA Brudac 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for IC/BPS Research. ( 29452126 )
2018
3
Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. ( 29331031 )
2018
4
Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-based Slow-release Delivery System in Patients With Interstitial Cystitis-Bladder Pain Syndrome: A Pilot Study. ( 29307733 )
2018
5
Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. ( 29392488 )
2018
6
Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. ( 29372285 )
2018
7
Endometriosis increased the risk of bladder pain syndrome/interstitial cystitis: A population-based study. ( 29318645 )
2018
8
Animal Model of Interstitial Cystitis/Bladder Pain Syndrome. ( 29385782 )
2018
9
A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. ( 29363787 )
2018
10
Extent of Hunner lesions: The relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. ( 29315774 )
2018
11
Bladder pain syndrome/interstitial cystitis is associated with asthma: A case-control study. ( 29441652 )
2018
12
The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. ( 29363792 )
2018
13
Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. ( 29385788 )
2018
14
Differences in Urodynamic Parameters According to the Presence of a Hunner Lesion in Women With Interstitial Cystitis/Bladder Pain Syndrome. ( 29385787 )
2018
15
Therapeutic effect of urine-derived stem cells for protamine/lipopolysaccharide-induced interstitial cystitis in a rat model. ( 28482861 )
2017
16
Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. ( 29265766 )
2017
17
Inhibition of microRNA-214 promotes epithelial-mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2. ( 28729638 )
2017
18
Expression of programmed death ligand-1 on bladder tissues is detected in a clinically and histologically well-defined interstitial cystitis cohort. ( 29277923 )
2017
19
Expression profile of urothelial transcription factors in bladder biopsies with interstitial cystitis. ( 28626955 )
2017
20
Treatment of ulcerative compared to non-ulcerative interstitial cystitis with hyperbaric oxygen: a pilot study. ( 29383031 )
2017
21
Interstitial cystitis intravesical therapy. ( 28791236 )
2017
22
Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. ( 28056917 )
2017
23
A new player in interstitial cystitis/bladder pain syndrome: platelet-activating factor - PAF and its connection to smoking. ( 28408637 )
2017
24
Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome. ( 29283084 )
2017
25
Re: Heparin and Alkalinized Lidocaine versus Alkalinized Lidocaine for Treatment of Interstitial Cystitis Symptoms. ( 27979536 )
2017
26
The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans. ( 29299202 )
2017
27
Significant Linkage Evidence for Interstitial Cystitis/Painful Bladder Syndrome on Chromosome 3. ( 28734863 )
2017
28
Somatic symptoms are sensitive in predicting interstitial cystitis/bladder pain syndrome. ( 28486876 )
2017
29
An Immunogenic Peptide, T2 Induces Interstitial Cystitis/Painful Bladder Syndrome: an Autoimmune Mouse Model for Interstitial Cystitis/Painful Bladder Syndrome. ( 28799018 )
2017
30
Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. ( 28595240 )
2017
31
Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. ( 28435032 )
2017
32
Efficacy, Side Effects, and Monitoring of Oral Cyclosporine in Interstitial Cystitis-Bladder Pain Syndrome. ( 28528859 )
2017
33
Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis. ( 28887515 )
2017
34
Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment. ( 28868507 )
2017
35
Designing a Mobile Health Application Prototype for the Management of Interstitial Cystitis/Painful Bladder Syndrome. ( 29295059 )
2017
36
Transurethral Resection Alone Vs Resection Combined With Therapeutic Hydrodistention as Treatment for Ulcerative Interstitial Cystitis: Initial Experience With Propensity Score Matching Studies. ( 27720770 )
2017
37
Kenalog Injection into Hunner's Lesions as a Treatment for Interstitial Cystitis/Bladder Pain Syndrome. ( 28878600 )
2017
38
Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: Evidence from a nested case-control study and a retrospective cohort study. ( 28471951 )
2017
39
Childhood bladder and bowel dysfunction predicts irritable bowel syndrome phenotype in adult interstitial cystitis/bladder pain syndrome patients. ( 28798827 )
2017
40
Naftopidil Improves Symptoms in a Rat Model of Tranilast-Induced Interstitial Cystitis. ( 28394500 )
2017
41
Sensory mapping of pelvic dermatomes in women with interstitial cystitis/bladder pain syndrome. ( 28628232 )
2017
42
Alexithymia and anesthetic bladder capacity in interstitial cystitis/bladder pain syndrome. ( 28789788 )
2017
43
Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. ( 28480984 )
2017
44
Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. ( 27976711 )
2016
45
Hydrodistention of the bladder for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC). ( 27092957 )
2016
46
Differences in Urodynamic Parameters between Women with Interstitial Cystitis/Bladder Pain Syndrome and Severe Overactive Bladder. ( 27130264 )
2016
47
F16357, a novel PAR1 antagonist improves urodynamic parameters in a rat model of Interstitial Cystitis. ( 27111354 )
2016
48
Re: Classic Interstitial Cystitis: Unrelated to BPS. ( 27321512 )
2016
49
Urothelial Functional Protein and Sensory Receptors in Patients with Interstitial Cystitis/Bladder Pain Syndrome with and Without Hunner's Lesion. ( 27575016 )
2016
50
Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. ( 26999787 )
2016

Variations for Interstitial Cystitis

Expression for Interstitial Cystitis

Search GEO for disease gene expression data for Interstitial Cystitis.

Pathways for Interstitial Cystitis

Pathways related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 BDNF CDH1 CXCL8 EGF HBEGF IL4
2
Show member pathways
13.37 BDNF CDH1 CXCL8 EGF IL4 IL6
3
Show member pathways
13.03 BDNF EGF HBEGF IL6 NGF P2RX3
4
Show member pathways
12.99 BDNF CDH1 CXCL8 EGF HBEGF IL4
5
Show member pathways
12.9 BDNF EGF HBEGF IL6 NGF
6
Show member pathways
12.81 BDNF EGF HBEGF IL4 IL6 NGF
7
Show member pathways
12.8 BDNF EGF IL4 IL6 NGF
8 12.62 CDH1 CXCL8 EGF IL4 IL6
9
Show member pathways
11.99 CXCL8 IL4 IL6
10 11.82 CXCL8 IL4 IL6
11 11.77 BDNF CXCL8 IL6 NGF TAC1
12 11.75 BDNF CXCL8 IL4 IL6
13 11.71 EGF HBEGF IL6
14 11.61 CXCL8 IL4 IL6
15 11.58 BDNF EGF NGF
16 11.47 CXCL8 HBEGF IL6
17 11.36 CXCL8 EGF IL4 IL6
18 11.3 CXCL8 IL4 IL6
19 10.88 CXCL8 IL6
20 10.88 CDH1 CXCL8 EGF HBEGF UPK3A
21 10.71 BDNF EGF
22 10.62 IL4 IL6
23 10.4 BDNF CDH1 CXCL8 EGF IL4 IL6

GO Terms for Interstitial Cystitis

Cellular components related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CXCL8 EGF HBEGF IL4 IL6 KNG1
2 extracellular region GO:0005576 9.36 BDNF CDH1 CXCL8 EGF HBEGF IL4
3 receptor complex GO:0043235 9.33 ADRB2 EGF P2RX3

Biological processes related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.81 IL6 KNG1 NGF TRPV1
2 cell-cell signaling GO:0007267 9.78 ADRB2 BDNF NGF TAC1
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.71 KNG1 TAC1 TRPV1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 EGF HBEGF IL6
5 response to pain GO:0048265 9.52 TAC1 TRPV1
6 negative regulation of ERBB signaling pathway GO:1901185 9.49 EGF HBEGF
7 activation of transmembrane receptor protein tyrosine kinase activity GO:0007171 9.46 ADRB2 EGF
8 positive regulation of acute inflammatory response GO:0002675 9.43 IL6 TAC1
9 behavioral response to pain GO:0048266 9.4 P2RX3 TRPV1
10 inflammatory response GO:0006954 9.35 CXCL8 IL6 KNG1 TAC1 TRPV1
11 regulation of protein localization to cell surface GO:2000008 9.32 BDNF EGF
12 diet induced thermogenesis GO:0002024 9.26 ADRB2 TRPV1
13 urinary bladder smooth muscle contraction GO:0014832 9.16 P2RX3 TRPV1
14 regulation of receptor activity GO:0010469 9.1 BDNF CXCL8 HBEGF IL4 IL6 NGF

Molecular functions related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.1 BDNF EGF HBEGF IL4 IL6 NGF

Sources for Interstitial Cystitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....